title: Highly effective protease inhibitors from variants of human pancreatic secretory trypsin inhibitor (hPSTI): an assessment of 3-D structure-based protein design.
abstract: The results of a protein design project are used to compare different predictive strategies with respect to protein-protein interactions. We have been able to generate variants of human pancreatic secretory trypsin inhibitor (hPSTI) optimized with respect to the affinity and specificity for human leukocyte elastase relative to trypsin and chymotrypsin, and in particular chymotrypsin. The extremely strong and specific human leukocyte elastase inhibitors were thus developed in three rounds of mutagenesis and two rounds of 3-D modelling; only 24 variants in total were synthesized, although variations at seven different amino acid positions were involved (i.e. from 20(7) possible variants). An excellent elastase inhibitor could be designed with the minimum of two amino acid exchanges. The value of structural modelling and actual structure determination is discussed in the light of the experimental results of the designed protein variants and the results of tertiary structure determinations of the free variant and the inhibitor-protease complex. Particular reference is given to the strategy to be followed in protein design projects in general and to the development of protease inhibitors in particular.
authors.affiliation: Department of Molecular Structure Research, Gesellschaft für Biotechnologische Forschung, Braunschweig, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Szardenings
authors.forename: B
authors.initials: B
authors.lastname: Vasel
authors.forename: H J
authors.initials: HJ
authors.lastname: Hecht
authors.forename: J
authors.initials: J
authors.lastname: Collins
authors.forename: D
authors.initials: D
authors.lastname: Schomburg
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D002417:Cattle; D002918:Chymotrypsin / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D019272:Leukocyte Elastase; D008958:Models, Molecular; D008969:Molecular Sequence Data; D016296:Mutagenesis; D010196:Pancreatic Elastase / Q000037:antagonists & inhibitors / Q000378:metabolism; D011480:Protease Inhibitors / Q000737:chemistry* / Q000378:metabolism; D011485:Protein Binding; D011487:Protein Conformation; D015202:Protein Engineering; D017434:Protein Structure, Tertiary; D017421:Sequence Analysis; D012965:Sodium Chloride / Q000494:pharmacology; D013379:Substrate Specificity; D014357:Trypsin / Q000378:metabolism; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism
chemical_list: D011480:Protease Inhibitors; D012965:Sodium Chloride; D014359:Trypsin Inhibitor, Kazal Pancreatic; D002918:Chymotrypsin; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase; D014357:Trypsin